Effects of tetrahydrohyperforin in mouse hippocampal slices: Neuroprotection, long-term potentiation and TRPC channels

Current Medicinal Chemistry

Volumn 21, Issue 30, 2014, Pages 3494-3506

  Montecinos Oliva, C ^a   Schuller A ^a,b   Parodi, J ^a   Melo, F ^a,b   Inestrosa, N C ^a,c,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Pontificia Universidad Católica de Chile   (Chile)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSIDAD DE MAGALLANES   (Chile)

Author keywords

Alzheimer's Disease; A oligomers; Hippocampus; Neuroprotection; Tetrahydrohyperforin; TRPC channels

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; AMYLOID BETA PROTEIN; LANTHANUM; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; OLIGOMER; TETRAHYDROHYPERFORIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TRANSIENT RECEPTOR POTENTIAL CHANNEL 7; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; UNCLASSIFIED DRUG; 1-(2-(3-(4-METHOXYPHENYL)PROPOXY)-4-METHOXYPHENYLETHYL)-1H-IMIDAZOLE; 1-OLEOYL-2-ACETYLGLYCEROL; DIACYLGLYCEROL; HYPERFORIN; IMIDAZOLE DERIVATIVE; PHLOROGLUCINOL; TERPENE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MECHANISM; ELECTROPHYSIOLOGICAL PROCEDURES; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; HYDROGEN BOND; LONG TERM POTENTIATION; MALE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MORRIS WATER MAZE TEST; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PHARMACOPHORE; SPATIAL MEMORY; SYNAPSE; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BINDING SITE; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; IN VITRO STUDY; METABOLISM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; BINDING SITES; DIGLYCERIDES; EXCITATORY POSTSYNAPTIC POTENTIALS; HIPPOCAMPUS; IMIDAZOLES; IN VITRO TECHNIQUES; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; MOLECULAR DOCKING SIMULATION; NEUROPROTECTIVE AGENTS; PHLOROGLUCINOL; PROTEIN STRUCTURE, TERTIARY; TERPENES; TRPC CATION CHANNELS;

EID: 84926308403     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140716091229     Document Type: Article

References (53)

1. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer's disease. Lancet, 2011, 377, 1019-31.
2. Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med., 2011, 1, a006189.
3. Tsai, L.-H.; Lee, M.-S.; Cruz, J. Cdk5, a therapeutic target for Alzheimer's disease? Biochim. Biophys. Acta, 2004, 1697, 137-142.
4. Dickson, D. W. Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J. Clin. Invest., 2004, 114, 23-27.
5. Lacor, P. N.; Buniel, M. C.; Chang, L.; Fernandez, S. J.; Gong, Y.; Viola, K. L.; Lambert, M. P.; Velasco, P. T.; Bigio, E. H.; Finch, C. E.; Krafft, G. A.; Klein, W. L. Synaptic targeting by Alzheimer'srelated amyloid beta oligomers. J. Neurosci., 2004, 24, 10191-10200.
6. Singer, A.; Wonnemann, M.; Müller, W. E. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J. Pharmacol. Exp. Ther., 1999, 290, 1363-1368.
7. Miller, A. L. St. Johńs Wort (Hypericum perforatum): Clinical effects on depression and other conditions. Altern. Med. Rev., 1998, 3, 18-26.
8. Klusa, V.; Germane, S.; Nöldner, M.; Chatterjee, S. S. Hypericum extract and hyperforin: memory-enhancing properties in rodents. Pharmacopsychiatry, 2001, 34 Suppl 1, S61-S69.
9. Dinamarca, M. C.; Cerpa, W.; Garrido, J.; Hancke, J. L.; Inestrosa, N. C. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloidbeta-deposits. Mol. Psychiatry, 2006, 11, 1032-1048.
10. Bilia, A. R.; Bergonzi, M. C.; Morgenni, F.; Mazzi, G.; Vincieri, F. F. Evaluation of chemical stability of St. John's wort commercial extract and some preparations. Int. J. Pharm., 2001, 213, 199-208.
11. Medina, M. a; Martínez-Poveda, B.; Amores-Sánchez, M. I.; Quesada, A. R. Hyperforin: more than an antidepressant bioactive compound? Life Sci., 2006, 79, 105-11.
12. Rozio, M.; Fracasso, C.; Riva, a; Morazzoni, P.; Caccia, S. Highperformance liquid chromatography measurement of hyperforin and its reduced derivatives in rodent plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2005, 816, 21-7.
13. Cerpa, W.; Hancke, J. L.; Morazzoni, P.; Bombardelli, E.; Riva, A.; Marin, P. P. The Hyperforin Derivative IDN5706 Occludes Spatial Memory Impairments and Neuropathological Changes in a Double Transgenic Alzheimer's Mouse Model. Curr. Alzheimer Res., 2010, 126-133.
14. Leuner, K.; Kazanski, V.; Müller, M.; Essin, K.; Henke, B.; Gollasch, M.; Harteneck, C.; Müller, W. E. Hyperforin-a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J., 2007, 21, 4101-11.
15. Tai, Y.; Feng, S.; Ge, R.; Du, W.; Zhang, X.; He, Z.; Wang, Y. TRPC6 channels promote dendritic growth via the CaMKIV-CREB pathway. J. Cell Sci., 2008, 121, 2301-2307.
16. Zhou, J.; Du, W.; Zhou, K.; Tai, Y.; Yao, H.; Jia, Y.; Ding, Y.; Wang, Y. Critical role of TRPC6 channels in the formation of excitatory synapses. Nat. Neurosci., 2008, 11, 741-743.
17. Griffith, T. N.; Varela-Nallar, L.; Dinamarca, M. C.; Inestrosa, N. C. Neurobiological Effects of Hyperforin and its Potential in Alzheimer's Disease Therapy. Curr. Med. Chem., 2010, 17, 391-406.
18. Varela-nallar, L.; Alfaro, I. E.; Serrano, F. G.; Parodi, J.; Inestrosa, N. C. Wingless-type family member 5A (Wnta-5a) stimulates synaptic differetntiation and function of glutamatergic synapses. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 10-15.
19. Toledo, E. M.; Inestrosa, N. C. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol. Psychiatry, 2010, 15, 272-85, 228.
20. Watkins, R. E.; Maglich, J. M.; Moore, L. B.; Wisely, G. B.; Noble, S. M.; Davis-searles, P. R.; Lambert, M. H.; Kliewer, S. A.; Redinbo, M. R.; Carolina, N.; Receptor, N. 2. 1 Å Crystal Structure of Human PXR in Complex with the St. John's Wort. Biochemistry, 2003, 42, 1430-1438.
21. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol., 1995, 245, 43-53.
22. Labute, P. LowModeMD-implicit low-mode velocity filtering applied to conformational search of macrocycles and protein loops. J. Chem. Inf. Model., 2010, 50, 792-800.
23. Tu, P.; Kunert-Keil, C.; Lucke, S.; Brinkmeier, H.; Bouron, A. Diacylglycerol analogues activate second messenger-operated calcium channels exhibiting TRPC-like properties in cortical neurons. J. Neurochem., 2009, 108, 126-138.
24. Harteneck, C.; Gollasch, M. Pharmacological modulation of diacylglycerol-sensitive TRPC3/6/7 channels. Curr. Pharm. Biotechnol., 2011, 12, 35-41.
25. Manabe, T.; Wyllie, D. J.; Perkel, D. J.; Nicoll, R. A. Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. J. Neurophysiol., 1993, 70, 1451-9.
26. Creager, B. Y. R.; Dunwiddiet, T.; Lynch, G. Paired-pulse and frequency facilitation in the ca1 region., 1980, 409-424.
27. Sheng, M.; Hoogenraad, C. C. The postsynaptic architecture of excitatory synapses: a more quantitative view. Annu. Rev. Biochem., 2007, 76, 823-47.
28. Cerpa, W.; Farías, G. G.; Godoy, J. a; Fuenzalida, M.; Bonansco, C.; Inestrosa, N. C. Wnt-5a occludes Abeta oligomer-induced depression of glutamatergic transmission in hippocampal neurons. Mol. Neurodegener., 2010, 5, 3.
29. Parodi, J.; Sepúlveda, F. J.; Roa, J.; Opazo, C.; Inestrosa, N. C.; Aguayo, L. G. Amyloid Causes Depletion of Synaptic Vesicles Leading to Neurotransmission Failure. J. Biol. Chem., 2010, 285, 2506-2514.
30. Shankar, G. M.; Walsh, D. M. Alzheimer's disease: synaptic dysfunction and Abeta. Mol. Neurodegener., 2009, 4.
31. Walsh, D. M.; Klyubin, I.; Fadeeva, J. V; Cullen, W. K.; Anwyl, R.; Wolfe, M. S.; Rowan, M. J.; Selkoe, D. J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 2002, 416, 535-539.
32. D'Hooge, R.; De Deyn, P. P. Applications of the Morris water maze in the study of learning and memory. Brain Res. Brain Res. Rev., 2001, 36, 60-90.
33. Li, Z.; Xu, J.; Xu, P.; Liu, S.; Yang, Z. Wnt/β-catenin signalling pathway mediates high glucose induced cell injury through activation of TRPC6 in podocytes. Cell Prolif., 2013, 46, 76-85.
34. Verotta, L.; Sterner, O.; Appendino, G.; Bombardelli, E.; Pilati, T. The Reaction of Hyperforin with Hydride Reducing Agents. European J. Org. Chem., 2006, 2006, 5479-5484.
35. Leuner, K.; Heiser, J. H.; Derksen, S.; Mladenov, M. I.; Fehske, C. J.; Schubert, R.; Gollasch, M.; Schneider, G.; Harteneck, C.; Chatterjee, S. S.; Mu, W. E. Simple 2, 4-Diacylphloroglucinols as Classic Transient Receptor Potential-6 Activators - Identification of a Novel Pharmacophore. Mol. Pharmacol., 2010, 77, 368-377.
36. Malenka, R. C.; Kauer, J. A.; Zucker, R. S.; Nicoll, R. A. Postsynaptic calcium is sufficient for potentiation of hippocampal synaptic transmission. Science (80-.)., 1988, 242, 81-84.
37. Soboloff, J.; Spassova, M.; Xu, W.; He, L.-P.; Cuesta, N.; Gill, D. L. Role of endogenous TRPC6 channels in Ca2+ signal generation in A7r5 smooth muscle cells. J. Biol. Chem., 2005, 280, 39786-39794.
38. Almaguer-Melian, W.; Cruz-Aguado, R.; Bergado, J. A. Synaptic plasticity is impaired in rats with a low glutathione content. Synapse, 2000, 38, 369-374.
39. Kusuki, T.; Imahori, Y.; Fujii, R.; Inokuchi, K.; Kimura, M.; Ueda, S. Potentiation of phosphoinositide-derived signals during LTP in intact rat brain. Neuroreport, 1998, 9, 2085-2088.
40. Hofmann, T.; Obukhov, A. G.; Schaefer, M.; Harteneck, C.; Gudermann, T.; Schultz, G. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature, 1999, 397, 259-263.
41. Ding, J.; Xiao, Y.; Lu, D.; Du, Y.-R.; Cui, X.-Y.; Chen, J. Effects of SKF-96365, a TRPC inhibitor, on melittin-induced inward current and intracellular Ca2+ rise in primary sensory cells. Neurosci. Bull., 2011, 27, 135-42.
42. Singh, A.; Hildebrand, M. E.; Garcia, E.; Snutch, T. P. The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. Br. J. Pharmacol., 2010, 160, 1464-1475.
43. Chang, W.; Park, J. M.; Kim, J.; Kim, S. J. TRPC-Mediated Current Is Not Involved in Endocannabinoid-Induced Short-Term Depression in Cerebellum. Korean J. Physiol. Pharmacol., 2012, 16, 139-44.
44. Song, M.; Chen, D.; Yu, S. P. The TRPC channel blocker SKF 96365 Inhibits Glioblastoma Cell Growth by Enhancing Reverse Mode of the Na(+)/Ca(2+) Exchanger and Increasing Intracellular Ca(2+);, 2014; pp. 1-45.
45. Querfurth, H. W.; LaFerla, F. M. Mechanisms of Disease Alzheimer's Disease. N. Engl. J. Med., 2010, 362, 329-344.
46. Wang, Q.; Walsh, D. M.; Rowan, M. J.; Selkoe, D. J.; Anwyl, R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well a. J. Neurosci., 2004, 24, 3370-8.
47. Lin, Y.; Zhang, J.; Fu, J.; Chen, F.; Wang, J.; Wu, Z.; Yuan, S. Hyperforin attenuates brain damage induced by transient middle cerebral artery occlusion (MCAO) in rats via inhibition of TRPC6 channels degradation. J. Cereb. Blood Flow & Metab., 2013, 33, 253-262.
48. Inestrosa, N. C.; Tapia-Rojas, C.; Griffith, T. N.; Carvajal, F. J.; Benito, M. J.; Rivera-Dictter, a; Alvarez, a R.; Serrano, F. G.; Hancke, J. L.; Burgos, P. V; Parodi, J.; Varela-Nallar, L. Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phos phorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer's disease: a possible effect on APP processing. Transl. Psychiatry, 2011, 1, e20.
49. Cai, R.; Ding, X.; Zhou, K. C.; Shi, Y.; Ge, R. L.; Ren, G.; Jin, Y. N.; Wang, Y. Z. Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells. Int. J. Cancer, 2009, 125, 2281-2287.
50. Jia, Y.; Zhou, J.; Tai, Y.; Wang, Y. TRPC channels promote cerebellar granule neuron survival. Nat. Neurosci., 2007, 10, 559-67.
51. Trebak, M.; Vazquez, G.; Bird, G. S. J.; Putney, J. W. The TRPC3/6/7 subfamily of cation channels. Cell Calcium, 2003, 33, 451-461.
52. Tanila, H. Wading pools, fading memories-place navigation in transgenic mouse models of Alzheimer's disease. Front. Aging Neurosci., 2012, 4, 11.
53. Kandel, B. a; Ekins, S.; Leuner, K.; Thasler, W. E.; Harteneck, C.; Zanger, U. M. No activation of human pregnane X receptor by hyperforin-related phloroglucinols. J. Pharmacol. Exp. Ther., 2014, 348, 393-400.